Patents by Inventor Benito Munoz

Benito Munoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20190248779
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 15, 2019
    Inventors: Daniel Parks, Benito Munoz
  • Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10344023
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 9, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190175584
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: November 21, 2018
    Publication date: June 13, 2019
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • Compounds for the treatment of tuberculosis
    Patent number: 10301294
    Abstract: Disclosed are compounds that can be used for treating tuberculosis.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 28, 2019
    Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS GENERAL HOSPITAL, BRIGHAM AND WOMEN'S HOSPITAL
    Inventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20190153000
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: April 7, 2017
    Publication date: May 23, 2019
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA
    Publication number: 20190055252
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Application
    Filed: July 23, 2018
    Publication date: February 21, 2019
    Applicant: THE BROAD INSTITUTE, INC.
    Inventors: EAMON COMER, NOBUTAKA KATO, CHRISTINA SCHERER, JESSICA BASTIEN, JEREMY DUVALL, TIMOTHY LEWIS, MORGANE SAYES, MATTHEW LEIGHTY, JUN PU, JENNIFER BEAUDOIN, BERTRAND BRAIBANT, BENITO MUNOZ
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10174014
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 8, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • METHODS OF TREATING PULMONARY DISEASES AND DISORDERS
    Publication number: 20180369209
    Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 27, 2018
    Applicant: Proteostasis Therapeutics, Inc.
    Inventors: John Miller, Cecilia M. Bastos, Benito Munoz
  • Kinase inhibitors and methods of use thereof
    Patent number: 10137122
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: November 27, 2018
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS
    Publication number: 20180327363
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Application
    Filed: December 23, 2015
    Publication date: November 15, 2018
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20180291006
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 11, 2018
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20180282352
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 4, 2017
    Publication date: October 4, 2018
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein
  • Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
    Patent number: 10064853
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 4, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • Compounds And Compositions For The Treatment Of Cancer
    Publication number: 20180244629
    Abstract: Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.
    Type: Application
    Filed: January 18, 2018
    Publication date: August 30, 2018
    Inventors: Timothy A. Lewis, Benito Munoz, Lucian De Waal, Heidi Greulich, Matthew Meyerson, Lara Nicole Gechijian
  • Compounds and methods for the treatment of malaria
    Patent number: 10059711
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: August 28, 2018
    Assignee: The Broad Institute, Inc.
    Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
  • COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY
    Publication number: 20180214419
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Application
    Filed: July 25, 2016
    Publication date: August 2, 2018
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10017503
    Abstract: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: July 10, 2018
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20180147187
    Abstract: The present disclosure features compounds such as those having the Formulae (IIa), (IIb), (IIc), (IId), (IIIa), and (IIIb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (IIa), (IIb), (IIc), (IId), (IIIa), or (IIIb).
    Type: Application
    Filed: January 12, 2006
    Publication date: May 31, 2018
    Applicant: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20180127400
    Abstract: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).
    Type: Application
    Filed: July 19, 2017
    Publication date: May 10, 2018
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Thiazole-based inhibitors of scavenger receptor BI
    Patent number: 9951055
    Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: April 24, 2018
    Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc.
    Inventors: Chris Dockendorff, Willmen Youngsaye, Partha Pratim Nag, Timothy A. Lewis, Sivaraman Dandapani, Benito Munoz, Patrick Faloon, Thomas Nieland, Monty Krieger, Miao Yu